- Home
- SGMT vs VOR Comparison
SGMT vs VOR Comparison
Compare SGMT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- VOR
- Stock Information
- Founded
- SGMT 2006
- VOR 2015
- Country
- SGMT United States
- VOR United States
- Employees
- SGMT N/A
- VOR N/A
- Industry
- SGMT
- VOR Biotechnology: Pharmaceutical Preparations
- Sector
- SGMT
- VOR Health Care
- Exchange
- SGMT Nasdaq
- VOR Nasdaq
- Market Cap
- SGMT 269.2M
- VOR 261.2M
- IPO Year
- SGMT 2023
- VOR 2021
- Fundamental
- Price
- SGMT $8.71
- VOR $1.98
- Analyst Decision
- SGMT Strong Buy
- VOR Buy
- Analyst Count
- SGMT 8
- VOR 6
- Target Price
- SGMT $27.25
- VOR $3.90
- AVG Volume (30 Days)
- SGMT 722.5K
- VOR 5.3M
- Earning Date
- SGMT 08-13-2025
- VOR 08-12-2025
- Dividend Yield
- SGMT N/A
- VOR N/A
- EPS Growth
- SGMT N/A
- VOR N/A
- EPS
- SGMT N/A
- VOR N/A
- Revenue
- SGMT N/A
- VOR N/A
- Revenue This Year
- SGMT N/A
- VOR N/A
- Revenue Next Year
- SGMT N/A
- VOR N/A
- P/E Ratio
- SGMT N/A
- VOR N/A
- Revenue Growth
- SGMT N/A
- VOR N/A
- 52 Week Low
- SGMT $1.73
- VOR $0.13
- 52 Week High
- SGMT $11.41
- VOR $3.29
- Technical
- Relative Strength Index (RSI)
- SGMT 55.77
- VOR 51.13
- Support Level
- SGMT $8.62
- VOR $1.62
- Resistance Level
- SGMT $10.06
- VOR $2.30
- Average True Range (ATR)
- SGMT 0.70
- VOR 0.21
- MACD
- SGMT -0.05
- VOR -0.08
- Stochastic Oscillator
- SGMT 58.06
- VOR 34.95
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VCAR33, Tremcel and Myelodysplastic Syndrome, Trem-cel+VCAR33 Treatment System, VADC45, CD123, CLL1, EMR2.